Preadmission statin use does not improve functional outcomes or prevent delayed ischemic events in patients with spontaneous subarachnoid hemorrhage

Pharmacotherapy. 2014 Aug;34(8):811-7. doi: 10.1002/phar.1436. Epub 2014 May 7.

Abstract

Study objective: To determine whether preadmission statin use in patients with spontaneous subarachnoid hemorrhage (SAH) is associated with improved functional outcomes and a lower incidence of delayed cerebral ischemic events compared with statin-naive patients with SAH.

Design: Prospective cohort study.

Setting: Neurosciences intensive care unit of a tertiary care hospital.

Patients: A total of 295 consecutive patients with SAH admitted between March 2006 and May 2013 who had complete medication histories; of these patients, 41 reported taking a statin prior to admission, and 254 were statin naive.

Intervention: All patients received clinical management for SAH according to hospital protocol for standard care that included acute statin therapy with enteral pravastatin 40 mg/day on hospital day 1 for up to 21 days.

Measurements and main results: Functional outcomes were assessed by using the modified Rankin Scale (mRS) at 14 days, 28 days, and 3 months. Delayed cerebral ischemia was assessed by using clinical evaluation and computed tomography. Patients taking statins prior to admission were more likely to have a history of diabetes mellitus, hypertension, coronary artery disease, and stroke. No significant difference in favorable neurologic outcome (mRS score 0-3) at 3 months was observed between the preadmission statin group compared with the statin-naive group (56.3% vs 72.4%, p=0.095). In multivariate logistic regression analysis, only age, severity of rupture, and coronary artery disease were less likely to predict a favorable neurologic outcome. No significant difference in the development of delayed cerebral ischemic events was observed between groups (p=0.48).

Conclusion: Statin use prior to admission did not improve functional outcomes or prevent delayed cerebral ischemic events in patients with SAH. Age, severity of rupture, and coronary artery disease were less likely to predict a favorable neurologic outcome at 3 months after discharge.

Keywords: functional outcome; ischemia; statin; subarachnoid hemorrhage; vasospasm.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Brain Ischemia / epidemiology
  • Brain Ischemia / etiology
  • Brain Ischemia / prevention & control*
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Incidence
  • Intensive Care Units
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pravastatin / administration & dosage
  • Pravastatin / therapeutic use*
  • Prospective Studies
  • Subarachnoid Hemorrhage / complications
  • Subarachnoid Hemorrhage / therapy*
  • Time Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pravastatin